Anvisa approves Gazyva for the treatment of lupus

Anvisa lupus treatment obinutuzumab Gazyva autoimmune disease

Brazil's National Health Surveillance Agency (Anvisa) has recommended the use of Gazyva (obinutuzumab) for the treatment of lupus. The medication, which is also used in some cancer cases, is intended for adult patients suffering from moderate to severe active lupus who are positive for autoantibodies and currently undergoing standard treatment.

Obinutuzumab is a humanized monoclonal antibody designed to cause the massive and prolonged elimination of B lymphocytes. These cells play a central role in the abnormal physiological processes that drive the development of lupus, a chronic and potentially serious autoimmune condition.

Anvisa noted that the benefits of this new indication include reduced disease activity, fewer exacerbations, and a sustained reduction in the need for corticosteroids. The agency highlighted that many patients currently struggle with recurrent flares or a dependency on corticosteroids, which carry significant long-term side effects.

The Ministry of Health warned that untreated lupus can lead to severe complications in organs such as the kidneys, skin, joints, and central nervous system, potentially resulting in death. Kidney failure is cited as a leading cause of death within the first five years following a lupus diagnosis.

Entities

Anvisa · Gazyva · Ministério da Saúde

Claims

What the coverage asserts, and how many sources carry each claim.

[● 3 SOURCES] Obinutuzumab is a humanized monoclonal antibody that promotes the massive and prolonged elimination of B lymphocytes. gazeta24h.com · portalacontecern.com.br · reporterbrasilia.com.br
[● 3 SOURCES] Untreated lupus can lead to serious complications in various organs and potentially death. gazeta24h.com · portalacontecern.com.br · reporterbrasilia.com.br
[● 3 SOURCES] The medication is indicated for adult patients with moderate to severe active lupus who are positive for autoantibodies and using standard treatment. gazeta24h.com · portalacontecern.com.br · reporterbrasilia.com.br
[● 3 SOURCES] Kidney failure is one of the main causes of death from lupus complications within the first five years of diagnosis. gazeta24h.com · portalacontecern.com.br · reporterbrasilia.com.br
[● 3 SOURCES] The treatment can lead to a sustained reduction in corticosteroid exposure. gazeta24h.com · portalacontecern.com.br · reporterbrasilia.com.br
[● 3 SOURCES] The new indication includes benefits such as reduced disease activity and lower occurrence of exacerbations. gazeta24h.com · portalacontecern.com.br · reporterbrasilia.com.br
[● 3 SOURCES] Anvisa has recommended the drug Gazyva (obinutuzumab) for treating lupus. gazeta24h.com · portalacontecern.com.br · reporterbrasilia.com.br